Role of interferon alpha-2a in the treatment of polycythemia vera

P. Foa, P. Massaro, S. Ribera, A. Iurlo, C. Mezzanotte, D. Giandalia, A. T. Maiolo

Research output: Contribution to journalArticle

Abstract

We studied the effects of recombinant interferon alpha-2a (IFN-alpha) in 36 patients with polycythemia vera (PV) previously treated with phlebotomy and/or conventional cytostatic agents. In each patient, after at least 2 months of discontinuation of any cytotoxic therapy, the hematocrit (Hmt) was first brought to normal value by phlebotomy; IFN-alpha treatment was then begun at a starting dose of 3,000,000 IU s.c. three times a week. Response to treatment, which was assessed monthly, was defined as persistent normalization of Hmt without concomitant phlebotomy; in non-responsive patients the initial IFN-alpha weekly dosage was progressively increased. Twenty patients were responsive with a median duration of response of 7 months (range 2-25+ months); out of these, 7 patients are still under treatment and responsive at 13+, 17+, 20+, 22+, 23+, 25+, 25+ months. These findings indicate that a cohort, although small, of patients with PV (19.4%) are persistently sensitive to IFN-alpha; in this subset of patients, this cytokine can therefore provide a useful treatment option, since, contrary to conventional therapeutic approaches such as radioactive phosphorus, cytostatic agents, or phlebotomy, IFN-alpha is devoid of harmful side effects.

Original languageEnglish
Pages (from-to)55-57
Number of pages3
JournalAmerican Journal of Hematology
Volume48
Issue number1
DOIs
Publication statusPublished - 1995

Fingerprint

Polycythemia Vera
Phlebotomy
Cytostatic Agents
Hematocrit
Therapeutics
interferon alfa-2a
Phosphorus
Reference Values
Cytokines

Keywords

  • Interferon alpha-2a
  • Myeloproliferative disorders
  • Polycythemia vera

ASJC Scopus subject areas

  • Hematology

Cite this

Foa, P., Massaro, P., Ribera, S., Iurlo, A., Mezzanotte, C., Giandalia, D., & Maiolo, A. T. (1995). Role of interferon alpha-2a in the treatment of polycythemia vera. American Journal of Hematology, 48(1), 55-57. https://doi.org/10.1002/ajh.2830480112

Role of interferon alpha-2a in the treatment of polycythemia vera. / Foa, P.; Massaro, P.; Ribera, S.; Iurlo, A.; Mezzanotte, C.; Giandalia, D.; Maiolo, A. T.

In: American Journal of Hematology, Vol. 48, No. 1, 1995, p. 55-57.

Research output: Contribution to journalArticle

Foa, P, Massaro, P, Ribera, S, Iurlo, A, Mezzanotte, C, Giandalia, D & Maiolo, AT 1995, 'Role of interferon alpha-2a in the treatment of polycythemia vera', American Journal of Hematology, vol. 48, no. 1, pp. 55-57. https://doi.org/10.1002/ajh.2830480112
Foa, P. ; Massaro, P. ; Ribera, S. ; Iurlo, A. ; Mezzanotte, C. ; Giandalia, D. ; Maiolo, A. T. / Role of interferon alpha-2a in the treatment of polycythemia vera. In: American Journal of Hematology. 1995 ; Vol. 48, No. 1. pp. 55-57.
@article{2ca5b33e6eff4571980d96b5c91b4930,
title = "Role of interferon alpha-2a in the treatment of polycythemia vera",
abstract = "We studied the effects of recombinant interferon alpha-2a (IFN-alpha) in 36 patients with polycythemia vera (PV) previously treated with phlebotomy and/or conventional cytostatic agents. In each patient, after at least 2 months of discontinuation of any cytotoxic therapy, the hematocrit (Hmt) was first brought to normal value by phlebotomy; IFN-alpha treatment was then begun at a starting dose of 3,000,000 IU s.c. three times a week. Response to treatment, which was assessed monthly, was defined as persistent normalization of Hmt without concomitant phlebotomy; in non-responsive patients the initial IFN-alpha weekly dosage was progressively increased. Twenty patients were responsive with a median duration of response of 7 months (range 2-25+ months); out of these, 7 patients are still under treatment and responsive at 13+, 17+, 20+, 22+, 23+, 25+, 25+ months. These findings indicate that a cohort, although small, of patients with PV (19.4{\%}) are persistently sensitive to IFN-alpha; in this subset of patients, this cytokine can therefore provide a useful treatment option, since, contrary to conventional therapeutic approaches such as radioactive phosphorus, cytostatic agents, or phlebotomy, IFN-alpha is devoid of harmful side effects.",
keywords = "Interferon alpha-2a, Myeloproliferative disorders, Polycythemia vera",
author = "P. Foa and P. Massaro and S. Ribera and A. Iurlo and C. Mezzanotte and D. Giandalia and Maiolo, {A. T.}",
year = "1995",
doi = "10.1002/ajh.2830480112",
language = "English",
volume = "48",
pages = "55--57",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Role of interferon alpha-2a in the treatment of polycythemia vera

AU - Foa, P.

AU - Massaro, P.

AU - Ribera, S.

AU - Iurlo, A.

AU - Mezzanotte, C.

AU - Giandalia, D.

AU - Maiolo, A. T.

PY - 1995

Y1 - 1995

N2 - We studied the effects of recombinant interferon alpha-2a (IFN-alpha) in 36 patients with polycythemia vera (PV) previously treated with phlebotomy and/or conventional cytostatic agents. In each patient, after at least 2 months of discontinuation of any cytotoxic therapy, the hematocrit (Hmt) was first brought to normal value by phlebotomy; IFN-alpha treatment was then begun at a starting dose of 3,000,000 IU s.c. three times a week. Response to treatment, which was assessed monthly, was defined as persistent normalization of Hmt without concomitant phlebotomy; in non-responsive patients the initial IFN-alpha weekly dosage was progressively increased. Twenty patients were responsive with a median duration of response of 7 months (range 2-25+ months); out of these, 7 patients are still under treatment and responsive at 13+, 17+, 20+, 22+, 23+, 25+, 25+ months. These findings indicate that a cohort, although small, of patients with PV (19.4%) are persistently sensitive to IFN-alpha; in this subset of patients, this cytokine can therefore provide a useful treatment option, since, contrary to conventional therapeutic approaches such as radioactive phosphorus, cytostatic agents, or phlebotomy, IFN-alpha is devoid of harmful side effects.

AB - We studied the effects of recombinant interferon alpha-2a (IFN-alpha) in 36 patients with polycythemia vera (PV) previously treated with phlebotomy and/or conventional cytostatic agents. In each patient, after at least 2 months of discontinuation of any cytotoxic therapy, the hematocrit (Hmt) was first brought to normal value by phlebotomy; IFN-alpha treatment was then begun at a starting dose of 3,000,000 IU s.c. three times a week. Response to treatment, which was assessed monthly, was defined as persistent normalization of Hmt without concomitant phlebotomy; in non-responsive patients the initial IFN-alpha weekly dosage was progressively increased. Twenty patients were responsive with a median duration of response of 7 months (range 2-25+ months); out of these, 7 patients are still under treatment and responsive at 13+, 17+, 20+, 22+, 23+, 25+, 25+ months. These findings indicate that a cohort, although small, of patients with PV (19.4%) are persistently sensitive to IFN-alpha; in this subset of patients, this cytokine can therefore provide a useful treatment option, since, contrary to conventional therapeutic approaches such as radioactive phosphorus, cytostatic agents, or phlebotomy, IFN-alpha is devoid of harmful side effects.

KW - Interferon alpha-2a

KW - Myeloproliferative disorders

KW - Polycythemia vera

UR - http://www.scopus.com/inward/record.url?scp=0028854972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028854972&partnerID=8YFLogxK

U2 - 10.1002/ajh.2830480112

DO - 10.1002/ajh.2830480112

M3 - Article

C2 - 7832194

AN - SCOPUS:0028854972

VL - 48

SP - 55

EP - 57

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 1

ER -